---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-25-000027"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:24:01.824045+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26

## Summary
- Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.
- GAAP and non-GAAP diluted EPS impact of approximately ($0.26) per share.
- Charge covers upfront and milestone payments from collaboration/license agreements.
- Biogen does not forecast such expenses due to uncertainty in timing and magnitude.
- Q2 2025 results not finalized; subject to closing procedures.

## SEC filing metadata
- accession: 0000875045-25-000027
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504525000027/0000875045-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504525000027/biib-20250707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-25-000027
- JSON: https://secwatch.observer/filing/0000875045-25-000027.json
- Plain text: https://secwatch.observer/filing/0000875045-25-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.